PMID- 16860660
OWN - NLM
STAT- MEDLINE
DCOM- 20060929
LR  - 20201215
IS  - 0065-230X (Print)
IS  - 0065-230X (Linking)
VI  - 95
DP  - 2006
TI  - NK cell receptors as tools in cancer immunotherapy.
PG  - 249-92
AB  - Natural killer (NK) cells were identified 30 years ago based on their ability to 
      "spontaneously" kill tumor cells. The basis for NK cell recognition and 
      activation is due to a variety of receptors that bind to specific ligands on 
      tumor cells and normal cells. Some of these receptors have the ability to inhibit 
      NK cell function, and other receptors activate NK cell function. Therapeutic 
      strategies for cancer therapy are being developed based on preventing NK cell 
      inhibition or using NK cell receptors to activate NK cells or T cells. There are 
      intriguing clinical data from studies of bone marrow transplantation that support 
      the idea that preventing NK cell inhibition by human leukocyte antigen (HLA) 
      class I molecules can be a means to promote graft-versus-leukemia (GvL) effects 
      and limit graft-versus-host disease (GvHD) in acute myeloid leukemia (AML) and 
      chronic myeloid leukemia (CML) patients. Experimental findings also support the 
      blockade of NK cell inhibitory receptors as a way to protect against leukemia 
      relapse. It may be possible to use our knowledge of NK cell activating receptors 
      and their ligands to immunize patients with modified tumor cells to promote 
      beneficial NK cell responses and development of host antitumor cytotoxic T 
      lymphocytes (CTLs). Finally, new data support the idea of using modified NK cell 
      receptors as a means to target patients' T cells against their own tumor cells 
      and induce long-term immunity against them. Tumors are essentially tissues that 
      have overcome normal regulation mechanisms, and therefore the ability to 
      distinguish normal cells from abnormal cells is a key part of selectively 
      attacking tumor cells. NK cells have various receptor systems designed to 
      recognize infected and abnormal cells. Understanding NK cell receptors and their 
      recognition mechanisms provides new tools for the development of immunotherapies 
      against cancer.
FAU - Sentman, Charles L
AU  - Sentman CL
AD  - Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, New 
      Hampshire 03756, USA.
FAU - Barber, Melissa A
AU  - Barber MA
FAU - Barber, Amorette
AU  - Barber A
FAU - Zhang, Tong
AU  - Zhang T
LA  - eng
GR  - AI07363/AI/NIAID NIH HHS/United States
GR  - AI51877/AI/NIAID NIH HHS/United States
GR  - CA101748/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United States
TA  - Adv Cancer Res
JT  - Advances in cancer research
JID - 0370416
RN  - 0 (Ligands)
RN  - 0 (Receptors, Immunologic)
RN  - 0 (Receptors, Natural Killer Cell)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Immune System/physiology
MH  - Immunotherapy/*methods
MH  - Killer Cells, Natural/*cytology/immunology
MH  - Ligands
MH  - Major Histocompatibility Complex
MH  - Neoplasms/*immunology/*therapy
MH  - Receptors, Immunologic/biosynthesis
MH  - Receptors, Natural Killer Cell
MH  - Time Factors
RF  - 230
EDAT- 2006/07/25 09:00
MHDA- 2006/09/30 09:00
CRDT- 2006/07/25 09:00
PHST- 2006/07/25 09:00 [pubmed]
PHST- 2006/09/30 09:00 [medline]
PHST- 2006/07/25 09:00 [entrez]
AID - S0065-230X(06)95007-6 [pii]
AID - 10.1016/S0065-230X(06)95007-6 [doi]
PST - ppublish
SO  - Adv Cancer Res. 2006;95:249-92. doi: 10.1016/S0065-230X(06)95007-6.